ICU-acquired weakness in critically ill patients at risk of malnutrition: risk factors, biomarkers, and early enteral nutrition impact

Qingliu Zheng, Changyun Liu, Lingying Le, Qiqi Wu, Zhihong Xu, Jiyan Lin, Qiuyun Chen

Table 3. Baseline characteristics of patients receiving different nutritional treatment approaches

Parameters EEN (n=96) PN (n=84) P-value Male, n (%) 63 (65.63) 50 (59.52) 0.398 Age, years, median (IQR) 74.0 (67.0-82.8) 72.5 (65.3-81.8) 0.497 BMI, kg/m2, median (IQR) 21.0 (19.4-20.8) 20.6 (19.2-22.1) 0.167 Underlying disease, n (%) Hypertension 42 (43.8) 44 (52.4) 0.247 Diabetes 28 (29.2) 22 (26.2) 0.657 Malignant tumor 17 (17.7) 11 (13.1) 0.394 MV, n (%) 16 (16.7) 15 (17.9) 0.833 TRF, g/L, median (IQR) 2.6 (2.2-3.1) 2.6 (2.1-3.2) 0.447 PAB, mg/L, median (IQR) 137.9 (97.3-169.5) 144.4 (96.5-180.0) 0.673 ALB, g/L, median (IQR) 34.5 (32.5-36.5) 34.7 (32.5-36.5) 0.937 CRP, mg/L, median (IQR) 73.6 (65.1-86.5) 75.9 (62.9-89.7) 0.654 IL-6, pg/mL, median (IQR) 56.0 (42.1-68.3) 58.6 (35.7-76.9) 0.500 BUN, mmol/L, median (IQR) 10.0 (8.6-10.9) 10.5 (8.9-12.3) 0.210 Cr, μmol/L, median (IQR) 129.8 (91.3-143.3) 120.6 (95.3-124.0) 0.946